

Human amniotic membrane accelerates healing in a hard-to-heal diabetic foot ulcer

PJ Idensohn

Wound Nurse Specialist, CliniCare Medical Centre, South Africa
 School of Nursing, Faculty of Health Sciences, University of the Free State, South Africa
 Corresponding author, email: trish@clinicaregroup.com

© Medpharm

Wound Healing Southern Africa 2023;16(1):27-29

Introduction

Human amniotic membrane (HAM) is acquired from the human placenta. This advanced regenerative therapy rich in growth factors, stem cells and cytokines, limits the extent of continuing inflammatory damage, decreases the microbial bioburden, and promotes progression into the proliferative phase of healing.¹ HAM provides a natural cellular scaffold for cellular adhesion facilitating keratinocyte migration to promote re-epithelialisation and enable remodelling to accelerate wound healing.¹ High quality studies with good evidence specify the safe and effective use of HAM in the management of diabetic foot ulcers.^{2,3}

A diabetic foot ulcer (DFU) is considered hard-to-heal when the wound surface area has not reduced by 50% after 4 weeks of appropriate moist wound management and offloading.² This case study aimed to evaluate the use of dehydrated HAM (dHAM) in the management of a hard-to-heal DFU.

Case study details

Gender	Male
Age	68 yrs
Medical & surgical history	<ul style="list-style-type: none"> Coronary bypass artery graft (2013) Type 2 diabetes mellitus Renal calculi +/-4 x Gout
Social habits	<ul style="list-style-type: none"> Non-smoker. Consumes 2 units of alcohol (16 g) daily
Wound Infection Continuum (WIC)	Colonised (patient immunocompromised)
Location of wound	Medial distal aspect of the right foot
Duration of wound	18 weeks
Wound history	Commenced as a blister on the plantar aspect of right hallux. Self-care. Surgical debridement followed by a table angiogram, right femoral stent, tibial angioplasty. Amputation of the right hallux.

Previous treatment of patient and wound	<p>Clinic visits twice a week included:</p> <ul style="list-style-type: none"> Blood glucose monitoring and control. Offloading of the affected area with the use of a postoperative shoe with an orthotic insert altered to specification. Sharp debridement. Infection and moist wound therapy included: antiseptic cleanses and soaks, varied topical antiseptic dressings, negative pressure wound therapy, non adhesive foams, silicone tape, and periwound skin protectant.
Wound assessment	<p>Tissue: 100% granulation uneven and pocketing from 4 to 10 o'clock Inflammation/Infection: colonised Moisture: <ul style="list-style-type: none"> 40% clear, serous, exudate Periwound macerated from 3.30 to 9 o'clock. Edges: Non-advancing, epibole from 4 to 10 o'clock Regeneration: Stalled closure, failing conservative therapy Social factors: <ul style="list-style-type: none"> A farmer who lives 3½ hours drive away in a rural area with his supportive family on a farm. Anxious – due to death threats Pain 3/10 No odour </p>
Wound treatment summary	<p>Weekly clinic visits included:</p> <ul style="list-style-type: none"> Antiseptic cleanse. Sharp debridement if required. Antiseptic soak. Sterile water rinse. dHAM applications on week 0, 2, and 4. Non-adherent silicone contact layer and a foam dressing. Offloading of the affected area with the use of a postoperative shoe with an orthotic insert altered to specification. Blood glucose monitoring and control.
Patient education	<p>Ongoing education provided regarding:</p> <ul style="list-style-type: none"> Blood glucose monitoring and control (HbA1c:6.6 mmol/l) Nutrition and alcohol intake, offloading, foot wear, exercise, regular position changes.



Method

Informed and signed consent obtained from the study participant according to the Protection of Personal Information Act, 2013 (Act No. 4 of 2013) South Africa.

- Wound was assessed and managed using TIMERS wound preparation.⁴
- The wound surface area was measured and calculated weekly, and




Figure 1: Wound closure




Figure 2: Exudate level

the results were plotted on a line graph.

- The wound exudate level was assessed weekly using the Bates Jensen Wound Assessment Tool measurement method.⁵
- Pain was assessed weekly using the Numeric Pain Rating scale.⁶
- Assessment of infection utilising the International Wound Infection Continuum (IWII) wound infection continuum was performed weekly.⁷

Summary of outcomes

- The wound area reduced by 45% at week 1 and 97% at week 5 (Figure 1).
- The exudate level reduced by 25% at week 1 and 50% at week 5 (Figure 2).
- Severity of pain decreased from 3/10 at week 0 to 0/10 at week 1 and remained 0/10 at week 5. This reduction is regarded as clinically significant.⁵
- The wound remained colonised from week 1 to week 5.
- No adverse events were observed.

Conclusion

The application of dHAM accelerated wound closure, reduced the pain experienced significantly and reduced the exudate level in an individual with a hard-to-heal DFU, in this case study. Larger clinical studies within the South African population are recommended.

References

1. Van de Vyver M, Idensohn PJ, Niesler CU. A regenerative approach to the pharmacological management of hard-to-heal wounds. *Biochimie*. 2022;196:131-42. <https://doi.org/10.1016/j.biochi.2022.01.006>.
2. Piagessi A, L  uchli S, Bassetto F, et al. EWMA document: advanced therapies in wound management: cell and tissue-based therapies, physical and biophysical therapies smart and IT based technologies. *J Wound Care*. 2018;27(Suppl 6a):S1-137. <https://doi.org/10.12968/jowc.2018.27.sup6a.s1>.
3. Su YN, Zhao DY, Li YH, et al. Human amniotic membrane allograft, a novel treatment for chronic diabetic foot ulcers: A systematic review and meta-analysis of randomised controlled trials. *Int Wound J*. 2020;17(3):753-64. <https://doi.org/10.1111/iwj.13318>.
4. Atkin L, Bu  ko Z, Conde Montero E, et al. Implementing TIMERS: the race against hard-to-heal wounds. *J Wound Care*. 2019;23(Suppl 3a):S1-50. <https://doi.org/10.12968/jowc.2019.28.sup3a.s1>.
5. Harris C, Bates-Jensen B, Parslow N, et al. Bates-Jensen wound assessment tool: pictorial guide validation project. *J Wound Ostomy Continence Nurs*. 2010;37(3):253-9. <https://doi.org/10.1097/won.0b013e3181d73aab>.
6. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. *Pain*. 2000;88(3):287-94. <https://doi.org/10.1016/>

s0304-3959(00)00339-0.

7. International Wound Infection Institute (IWII). *Wound Infection in Clinical Practice*. Wounds International. 2022

Disclosure: Printing of the original poster was done by NextBiosciences. The author has received reimbursement for presentations from NextBiosciences.

